Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality, day 60 21% Improvement Relative Risk Mortality, day 28 13% Mortality, day 14 29% WHO score 0% no CI Hospitalization time -6% Domazet Bugarin et al. NCT05384574 Vitamin D RCT ICU Is very late treatment with vitamin D beneficial for COVID-19? RCT 152 patients in Croatia (November 2021 - May 2022) Lower mortality with vitamin D (not stat. sig., p=0.2) Domazet Bugarin et al., Nutrients, doi:10.3390/nu15051234 Favors vitamin D Favors control
Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients—Randomized Controlled Trial
Domazet Bugarin et al., Nutrients, doi:10.3390/nu15051234, NCT05384574 (history)
Domazet Bugarin et al., Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients—Randomized Controlled Trial, Nutrients, doi:10.3390/nu15051234, NCT05384574
Feb 2023   Source   PDF  
  All Studies   Meta
Very late stage RCT 155 ICU patients in Croatia with low vitamin D levels, showing no significant differences with 10,000IU cholecalciferol daily. Calcifediol or calcitriol, which avoids several days delay in conversion, may be more successful, especially with this very late stage usage.
The baseline mean age and median WHO scores for the treatment and control groups are both higher than the respective values reported for all patients combined, which is not possible.
The trial was registered after completion in May 2022.
risk of death, 21.0% lower, RR 0.79, p = 0.20, treatment 30 of 75 (40.0%), control 39 of 77 (50.6%), NNT 9.4, day 60.
risk of death, 12.5% lower, RR 0.87, p = 0.61, treatment 23 of 75 (30.7%), control 27 of 77 (35.1%), NNT 23, day 28.
risk of death, 28.9% lower, RR 0.71, p = 0.49, treatment 9 of 75 (12.0%), control 13 of 77 (16.9%), NNT 20, day 14.
WHO score, no change, RR 1.00, p = 0.70, treatment 75, control 77, day 28.
hospitalization time, 5.6% higher, relative time 1.06, p = 0.76, treatment 75, control 77.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Domazet Bugarin et al., 28 Feb 2023, Randomized Controlled Trial, Croatia, peer-reviewed, 9 authors, study period November 2021 - May 2022, dosage 10,000IU days 1-14, trial NCT05384574 (history).
Contact: (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: nutrients Article Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients—Randomized Controlled Trial Josipa Domazet Bugarin 1 , Svjetlana Dosenovic 1 , Darko Ilic 1 , Nikola Delic 1 , Ivana Saric 1 , Ivo Ugrina 2 , Sanda Stojanovic Stipic 1 , Bozidar Duplancic 1 and Lenko Saric 1, * 1 2 * Citation: Domazet Bugarin, J.; Department of Anesthesiology, Reanimatology and Intensive Care, University Hospital Split, 21000 Split, Croatia Intellomics Ltd., 21000 Split, Croatia Correspondence: Abstract: COVID-19 symptoms vary from asymptomatic cases to moderate and severe illness with patients needing hospitalization and intensive care treatment. Vitamin D is associated with severity of viral infections and has an immune-modulatory effect in immune response. Observational studies showed a negative association of low vitamin D levels and COVID-19 severity and mortality outcomes. In this study, we aimed to determine whether daily supplementation of vitamin D during intensive care unit (ICU) stay in COVID-19 patients with severe illness affects clinically relevant outcomes. Patients with COVID-19 disease in need of respiratory support admitted to the ICU were eligible for inclusion. Patients with low vitamin D levels were randomized into one of two groups: the intervention group received daily supplementation of vitamin D and the control group did not receive vitamin D supplementation. In total, 155 patients were randomized: 78 into the intervention group and 77 into the control group. There was no statistically significant difference in number of days spent on respiratory support, although the trial was underpowered for the main outcome. There was no difference in any of the secondary outcomes analyzed between two groups. Our study suggests no benefit in vitamin D supplementation to patients with severe COVID-19 disease admitted to the ICU and in need of respiratory support in any of the analyzed outcomes. Dosenovic, S.; Ilic, D.; Delic, N.; Saric, I.; Ugrina, I.; Stojanovic Stipic, S.; Keywords: vitamin D; ICU; COVID-19; respiratory support; mechanical ventilation; ARDS Duplancic, B.; Saric, L. Vitamin D Supplementation and Clinical Outcomes in Severe COVID-19 Patients—Randomized Controlled
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop